GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » Gross Profit

HLS Therapeutics (HLS Therapeutics) Gross Profit : $55.45 Mil (TTM As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is HLS Therapeutics Gross Profit?

HLS Therapeutics's gross profit for the three months ended in Dec. 2023 was $13.33 Mil. HLS Therapeutics's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $55.45 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. HLS Therapeutics's gross profit for the three months ended in Dec. 2023 was $13.33 Mil. HLS Therapeutics's Revenue for the three months ended in Dec. 2023 was $15.86 Mil. Therefore, HLS Therapeutics's Gross Margin % for the quarter that ended in Dec. 2023 was 84.03%.

HLS Therapeutics had a gross margin of 84.03% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of HLS Therapeutics was 96.50%. The lowest was 28.22%. And the median was 93.54%.

Warning Sign:

HLS Therapeutics Inc gross margin has been in long-term decline. The average rate of decline per year is -1.6%.


HLS Therapeutics Gross Profit Historical Data

The historical data trend for HLS Therapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Gross Profit Chart

HLS Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.23 52.48 56.04 56.49 55.45

HLS Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.16 13.31 14.64 14.17 13.33

Competitive Comparison of HLS Therapeutics's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Gross Profit falls into.



HLS Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

HLS Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=63.074 - 7.624
=55.45

HLS Therapeutics's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=15.863 - 2.533
=13.33

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $55.45 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

HLS Therapeutics's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=13.33 / 15.863
=84.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


HLS Therapeutics  (OTCPK:HLTRF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

HLS Therapeutics had a gross margin of 84.03% for the quarter that ended in Dec. 2023 => Durable competitive advantage


HLS Therapeutics Gross Profit Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


HLS Therapeutics (HLS Therapeutics) Business Description

Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.

HLS Therapeutics (HLS Therapeutics) Headlines

From GuruFocus

Automodular Corp. (TSX:AM) - Strong Buy

By Elliot Luchansky, CFA Elliot Luchansky, CFA 03-21-2013